Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Treatment of canine mast cell tumors with CCNU (lomustine).

Tytuł :
Treatment of canine mast cell tumors with CCNU (lomustine).
Autorzy :
Rassnick KM; Harrington Oncology Program, Tufts University, School of Veterinary Medicine, North Grafton, MA 01536, USA. />Moore AS
Williams LE
London CA
Kintzer PP
Engler SJ
Cotter SM
Pokaż więcej
Źródło :
Journal of veterinary internal medicine [J Vet Intern Med] 1999 Nov-Dec; Vol. 13 (6), pp. 601-5.
Typ publikacji :
Clinical Trial; Journal Article
Język :
English
Imprint Name(s) :
Publication: <2010-> : Malden, MA : Wiley Periodicals
Original Publication: Philadelphia : J.B. Lippincott Co., [c1987-
MeSH Terms :
Nasal Cavity*
Antineoplastic Agents, Alkylating/*therapeutic use
Dog Diseases/*drug therapy
Lomustine/*therapeutic use
Mast-Cell Sarcoma/*veterinary
Nose Neoplasms/*veterinary
Skin Neoplasms/*veterinary
Animals ; Antineoplastic Agents, Alkylating/adverse effects ; Dogs ; Lomustine/adverse effects ; Mast-Cell Sarcoma/drug therapy ; Neutropenia/chemically induced ; Nose Neoplasms/drug therapy ; Skin Neoplasms/drug therapy ; Treatment Outcome
Substance Nomenclature :
0 (Antineoplastic Agents, Alkylating)
7BRF0Z81KG (Lomustine)
Entry Date(s) :
Date Created: 19991210 Date Completed: 19991216 Latest Revision: 20190513
Update Code :
20210209
DOI :
10.1892/0891-6640(1999)013<0601:tocmct>2.3.co;2
PMID :
10587263
Czasopismo naukowe
The efficacy and toxicity of CCNU (1-[2-chloroethyl]3-cyclohexyl-1-nitrosourea) were evaluated in 23 dogs with measurable mast cell tumors (MCT). Twenty-two dogs had cutaneous MCT and 1 dog had an intranasal MCT Nineteen (83%) dogs had biopsy of their original mass performed and 4 (17%) had aspiration cytology of masses. Of the 19 tumors histologically graded, 1 (5%) neoplasm was classified as grade I, 10 (53%) were grade II, and the remaining 8 (42%) were grade III. Dogs were treated with CCNU at a dosage of 90 mg/m2 body surface area every 3 weeks. Response could be evaluated in 19 dogs. Eight of the 19 dogs (42%) had a measurable response to CCNU. One dog had a durable complete response for 440 days. Seven dogs (37%) had a partial response for a median and mean duration of 77 days and 109 days, respectively (range, 21-254 days). Treatment with CCNU resulted in stable disease in 6 dogs (32%) for a median and mean duration of 78 days and 122 days, respectively (range, 42-347 days). The acute dose-limiting toxicity was neutropenia 7 days after administration of CCNU. The median and mean neutrophil counts 7 days after CCNU were 1,452 cells/microL and 1,683 cells/microL, respectively (n = 17). Other toxicoses were uncommon. CCNU should be considered an active agent in the treatment of MCT in dogs.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies